Form 4: INSMED CFO Sara Bonstein Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, executed a series of transactions on June 23, 2025, exercising stock options at low prices and subsequently selling a portion of the acquired shares at significantly higher market prices under a Rule 10b5-1 trading plan.

Summary

• Sara Bonstein, Chief Financial Officer of INSMED Inc. (INSM), engaged in stock transactions on June 23, 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
• She exercised stock options to acquire 35,253 shares of common stock at an exercise price of $18.95 per share.
• Additionally, she exercised stock options to acquire 12,636 shares of common stock at an exercise price of $19.74 per share.
• Following these acquisitions, she sold 49,104 shares of common stock at a weighted average price of $101.71 per share, with individual sales ranging from $101.04 to $102.03.
• She also sold an additional 8,661 shares of common stock at a weighted average price of $102.15 per share, with individual sales ranging from $102.04 to $102.61.
• The transactions resulted in a net decrease of 9,876 shares in her direct beneficial ownership of common stock (57,765 shares sold minus 47,889 shares acquired through exercise).
• Her beneficial ownership of common stock after all reported transactions is 93,536 shares.
• Her beneficial ownership of stock options after all reported transactions includes 99,007 options with an exercise price of $18.95 and 25,124 options with an exercise price of $19.74.

Sentiment

Score: 8

Explanation: The sentiment is positive for the reporting person due to significant personal financial gains from exercising options at low prices and selling at high market prices. The use of a 10b5-1 plan also indicates compliant and pre-planned activity.

Positives

• The CFO realized significant personal financial gains by exercising stock options at low prices ($18.95 and $19.74) and selling the resulting shares at much higher market prices (weighted averages of $101.71 and $102.15).
• The transactions were conducted under a Rule 10b5-1 trading plan, which indicates pre-planning and compliance with SEC regulations, reducing concerns about opportunistic insider trading.

Negatives

• The net sale of shares by a key executive, while part of a pre-planned program, could be interpreted by some investors as a slight negative signal regarding future company prospects, although this is often a routine part of executive compensation and liquidity management.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions by a Chief Financial Officer, which are common across all industries as part of executive compensation and personal financial planning. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The net sale of shares by a key executive, while part of a pre-planned program, could be viewed by some shareholders as a slight negative signal, though the overall impact is likely minimal given the routine nature of such transactions.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The transactions demonstrate the realization of value from executive compensation, which is a positive for the individual CFO.

Key Dates

Keywords

INSMED Inc., INSM, Sara Bonstein, Chief Financial Officer, CFO, SEC Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1 Plan, Equity Compensation, Beneficial Ownership